- Home
- FSP vs ABOS Comparison
FSP vs ABOS Comparison
Compare FSP & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSP | ABOS |
|---|---|---|
| Founded | 1981 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.3M | 113.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FSP | ABOS |
|---|---|---|
| Price | $0.97 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 854.0K | 165.7K |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,497,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $0.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $0.86 |
| 52 Week High | $2.21 | $2.46 |
Technical Indicators
Market Signals| Indicator | FSP | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 33.51 | 53.23 |
| Support Level | $1.39 | $1.75 |
| Resistance Level | $1.04 | $2.03 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 47.05 | 82.08 |
Price Performance
Historical ComparisonAbout FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.